ClinicalTrials.gg
CompletedNCT05625971NIRVANAUpdated Jan 7, 2026

Non-invasive MRD Assessment in Multiple Myeloma

An observational study in Myeloma, sponsored by Rajshekhar Chakraborty, MD. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Rajshekhar Chakraborty, MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 502 studies in Neoplasms, Plasma Cell with a site in United States — 26 open to participants now, 43 under way, 2 of them phase 3. Neoplasms, Plasma Cell · United States.

Enrollment
32nd of 42
36 · median 159
Started
2022
with 6 others
Observational
42 of 502
7 open now
Registered
477th of 502
by date

Among the 502 studies in Neoplasms, Plasma Cell with a site in United States, this one is the 32nd largest by enrollment of the 42 observational ones that give a count, is one of 7 that started in 2022, is one of 42 observational ones, and was the 477th registered.

Neoplasms, Plasma Cell

710 studies on the registry are indexed under Neoplasms, Plasma Cell; 79 are open to participants now.

Browse Neoplasms, Plasma Cell studies →

Open to participants now

26 of the 502 studies in Neoplasms, Plasma Cell with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 58 Neoplasms, Plasma Cell studies recruiting now, 34 (59%) set no upper age limit and 12 (21%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Neoplasms, Plasma Cell with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously treated multiple myeloma. The long-term goal of this study is to investigate whether non-invasive methods for MRD assessment can replace bone marrow aspiration and biopsy in a substantial percentage of participants with multiple myeloma.

Read the detailed description

There is an unmet clinical need for an easier, non-invasive, and reliable method to perform MRD assessments that can be used in clinical trials and routine practice. The two non-invasive modalities that are most promising for MRD assessment are liquid biopsy to detect circulating tumor cells (CTCs) and functional imaging to detect focal myeloma lesions. However, there are no prospective data on the sensitivity and specificity of non-invasive MRD assessment with respect to the gold standard of bone marrow sampling.

03

Conditions studied

  • Myeloma

Keywords

  • Liquid biopsy
  • Minimal Residual Disease (MRD)
  • Functional imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with newly diagnosed or previously treated myeloma who are initiating a new line of therapy will be recruited.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age ≥18 years
  • Patients with newly diagnosed multiple myeloma
  • Patients with previously treated multiple myeloma with a maximum of two
  • Expected of greater than one year and intention to start a new line of treatment

Exclusion criteria

Exclusion Criteria:

  • Patients without cognitive capacity to give for participation
  • Patients with to MRI, which include the following:
  • Claustrophobia, which, at investigator's discretion, would prohibit patient from undergoing whole body diffusion-weighted magnetic resonance imaging (WB-DWI)
  • Pacemaker
  • Metallic implants, which would prohibit patient from undergoing MRI All subjects will be screened for any contraindication to MRI as per their guidelines at the time of patient enrollment.
  • Patients must not receive granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) injection within 1 week prior to WB-DWI.
  • Patients must not have been initiated on treatment prior to baseline disease assessment by bone marrow aspiration/ and/or WB-DWI Up to 160 mg of dexamethasone (or equivalent) and/or 1 dose of bortezomib (+/- Cyclophosphamide-Dexamethasone) is allowed prior to disease assessment by bone marrow aspiration and WB-DWI.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Myeloma Group

    Patients with newly diagnosed and previously treated multiple myeloma will receive bone marrow sampling and functional imaging.

    Other: MRD Assessment

Interventions

  • OtherMRD Assessment

    MRD assessment includes liquid biopsy and functional imaging. Liquid biopsy will be performed by the Adaptive ClonoSEQ® assay in peripheral blood. Functional imaging will be performed by whole body diffusion-weighted magnetic resonance imaging (WB-DWI).

06

What researchers measure

Primary outcomes

  1. Sensitivity of non-invasive MRD assessment

    MRD assessment includes liquid biopsy and functional imaging.

    Time frame: 6 months

  2. Specificity of non-invasive MRD assessment

    MRD assessment includes liquid biopsy and functional imaging.

    Time frame: 6 months

Secondary outcomes

  1. Sensitivity of two MRD-testing algorithms

    Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients

    Time frame: 6 months

  2. Specificity of two MRD-testing algorithms

    Combining liquid biopsy, functional imaging, and bone marrow sampling against the reference of bone marrow sampling in patients

    Time frame: 6 months

  3. Progression Free Survival

    The progression-free survival (PFS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling)

    Time frame: 2 years

  4. Overall Survival

    The overall survival (OS) will be calculated of patients who are MRD-positive and MRD-negative on each modality (liquid biopsy, functional imaging, and bone marrow sampling)

    Time frame: 2 years

07

Study locations

1 site
  • New York Presbyterian Hospital/Columbia University Irving Medical Center
    New York, New York 10032, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Dec 2025, 39 months.

Of 31 observational studies under Neoplasms, Plasma Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 148. This study's 39 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Nov 23, 2022
StartActual
Sep 14, 2022
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05625971
Lead sponsor
Rajshekhar Chakraborty, MD
Collaborators
Hope Foundation
Responsible party
Rajshekhar Chakraborty, MD (Assistant Professor of Medicine, Columbia University) — Sponsor-investigator
First posted
Nov 23, 2022
Start date
Sep 14, 2022
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Jan 7, 2026

Study contacts

Chakraborty Chakraborty, MD
principal investigator · Columbia University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion